XML 32 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Merger and Financing - Merger with Histogenics (Details) - USD ($)
1 Months Ended
Dec. 31, 2019
Oct. 04, 2019
Sep. 27, 2019
May 08, 2019
Jan. 31, 2018
Sep. 26, 2019
Dec. 31, 2018
Merger and Financing              
Cash and cash equivalents $ 7,444,052           $ 1,628,136
Accounts payable (1,895,613)           $ (3,277,525)
Asset purchase agreement, cash consideration 8,500,000            
Histogenics              
Merger and Financing              
Acquisition cost incurred     $ 4,900,000        
Acquisition cost paid in cash     2,600,000        
Acquisition cost paid with equity     2,300,000        
Cash and cash equivalents     302,000        
Asset held for sale     7,000,000        
Accounts payable     (1,106,000)        
Net assets acquired     $ 6,196,000        
Asset purchase agreement, cash consideration       $ 6,500,000      
Percentage of purchase price increase per month   10.00%          
Histogenics | Level 2              
Merger and Financing              
Quoted price of assets held for sale of NeoCart 7,000,000.0            
Neocart | Level 2              
Merger and Financing              
Quoted price of assets held for sale of NeoCart $ 7,000,000.0            
Former Ocugen equity holders | Histogenics              
Merger and Financing              
Ownership (as a percent)     84.25%        
Stockholders of Histogenics immediately before the Merger | Histogenics              
Merger and Financing              
Ownership (as a percent)           15.75%  
Histogenics              
Merger and Financing              
Upfront cash payment received for license granted to MEDINET         $ 10,000,000.0